First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Titel:
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Auteur:
Melichar, B. Koralewski, P. Ravaud, A. Pluzanska, A. Bracarda, S. Szczylik, C. Chevreau, C. Filipek, M. Delva, R. Sevin, E. Négrier, S. McKendrick, J. Santoro, A. Pisa, P. Escudier, B.